Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review

Virus Like Particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus

(2020) Himanshu Garg et al.   Scientific Reports

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

(2020) Xiaobo Yang et al.   Lancet Respiratory Medicine

Technological challenges in the preclinical development of an HIV nanovaccine candidate

(2020) Tamara G. Dacoba et al.   Drug Delivery and Translational Research

Advancements in prophylactic and therapeutic nanovaccines

(2020) Prateek Bhardwaj et al.   Acta Biomaterialia

A comprehensive insight towards Pharmaceutical Aspects of Graphene Nanosheets

(2020) Fatemeh Emadi et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Gold nanostars-diagnosis, bioimaging and biomedical applications

(2020) Seyyed Mojtaba Mousavi et al.   DRUG METABOLISM REVIEWS

A Review of SARS-CoV-2 and the Ongoing Clinical Trials

(2020) Yung-Fang Tu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

O/W Nanoemulsion as an Adjuvant for an Inactivated H3N2 Influenza Vaccine: Based on Particle Properties and Mode of Carrying

(2020) Lanhua Zhao et al.   International Journal of Nanomedicine

New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes

(2020) Mario Amacker et al.   npj Vaccines

Recent Progress on the Versatility of Virus-Like Particles

(2020) Ciying Qian et al.   Vaccines

Better Adjuvants for Better Vaccines: Progress in Adjuvant Delivery Systems, Modifications, and Adjuvant–Antigen Codelivery

(2020) Zhi-Biao Wang et al.   Vaccines

Antibody-Dependent Cellular Phagocytosis of HIV-1-Infected Cells Is Efficiently Triggered by IgA Targeting HIV-1 Envelope Subunit gp41

(2020) Maxence Duchemin et al.   Frontiers in Immunology

Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses

(2020) Tania Gupta et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Novel versatile 3D bio-scaffold made of natural biocompatible hagfish exudate for tissue growth and organoid modeling

(2020) Mahsa Borzouyan Dastjerdi et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated Diseases

(2020) Pola Olczak et al.   Vaccines

Ultra-sensitive viral glycoprotein detection NanoSystem toward accurate tracing SARS-CoV-2 in biological/non-biological media

(2020) Seyyed Alireza Hashemi et al.   BIOSENSORS & BIOELECTRONICS

Recent biotechnological approaches for treatment of novel COVID-19: from bench to clinical trial

(2020) Seyyed Mojtaba Mousavi et al.   DRUG METABOLISM REVIEWS

PLGA encapsulated inactivated-viral vaccine: Formulation and evaluation of its protective efficacy against viral haemorrhagic septicaemia virus (VHSV) infection in olive flounder (Paralichthys olivaceus) vaccinated by mucosal delivery routes

(2019) Sajal Kole et al.   VACCINE

Pharmacokinetics and Pharmacodynamics Modeling and Simulation Systems to Support the Development and Regulation of Liposomal Drugs

(2019) Hua He et al.   Pharmaceutics

Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization

(2019) Ning Wang et al.   JOURNAL OF CONTROLLED RELEASE

Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms

(2019) Philip J.M. Brouwer et al.   Current Opinion in HIV and AIDS

Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement

(2019) Atin Khalaj‐Hedayati et al.   Influenza and Other Respiratory Viruses

A phase 1, randomized, observer blind, antigen and adjuvant dosage finding clinical trial to evaluate the safety and immunogenicity of an adjuvanted, trivalent subunit influenza vaccine in adults ≥ 65 years of age

(2019) Gillis Otten et al.   VACCINE

Recent Advances in Nanovaccines Using Biomimetic Immunomodulatory Materials

(2019) Vijayan et al.   Pharmaceutics

Development of Universal Influenza Vaccines Targeting Conserved Viral Proteins

(2019) Jazayeri et al.   Vaccines

Nanoparticle vaccines against viral infections

(2018) Fernando B. Sulczewski et al.   ARCHIVES OF VIROLOGY

Loading dendritic cells with gold nanoparticles (GNPs) bearing HIV-peptides and mannosides enhance HIV-specific T cell responses

(2018) Núria Climent et al.   Nanomedicine-Nanotechnology Biology and Medicine

Development of a Virosomal RSV Vaccine Containing 3D-PHAD® Adjuvant: Formulation, Composition, and Long-Term Stability

(2018) J. Lederhofer et al.   PHARMACEUTICAL RESEARCH

Advances in HIV-1 Vaccine Development

(2018) Yong Gao et al.   Viruses-Basel

Antibody-mediated immune exclusion of HIV

(2017) Ruth M. Ruprecht et al.   Current Opinion in HIV and AIDS

Single-Dose Hepatitis A Immunization: 7.5-Year Observational Pilot Study in Nicaraguan Children to Assess Protective Effectiveness and Humoral Immune Memory Response

(2016) Orlando Mayorga et al.   JOURNAL OF INFECTIOUS DISEASES

Fusion of Enveloped Viruses in Endosomes

(2016) Judith M. White et al.   TRAFFIC

Self-assembling protein nanoparticles in the design of vaccines

(2016) Jacinto López-Sagaseta et al.   Computational and Structural Biotechnology Journal

Current and next generation influenza vaccines: Formulation and production strategies

(2015) Peter C. Soema et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Effect of Chemical Stabilizers on the Thermostability and Infectivity of a Representative Panel of Freeze Dried Viruses

(2015) Boris Pastorino et al.   PLoS One

Vaccines for the 21st century

(2014) I. Delany et al.   EMBO Molecular Medicine

A Peptide-Based Nanofibrous Hydrogel as a Promising DNA Nanovector for Optimizing the Efficacy of HIV Vaccine

(2014) Yue Tian et al.   NANO LETTERS

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice

(2014) Christopher M. Coleman et al.   VACCINE

Bioreducible alginate-poly(ethylenimine) nanogels as an antigen-delivery system robustly enhance vaccine-elicited humoral and cellular immune responses

(2013) Ping Li et al.   JOURNAL OF CONTROLLED RELEASE

Gold nanoparticle–M2e conjugate coformulated with CpG induces protective immunity against influenza A virus

(2013) Wenqian Tao et al.   Nanomedicine

Development of a virosomal malaria vaccine candidate: from synthetic peptide design to clinical concept validation

(2012) Gerd Pluschke et al.   Future Virology

Successful Memory Response following a Booster Dose with a Virosome-Formulated Hepatitis A Vaccine Delayed Up to 11 Years

(2011) Christoph Hatz et al.   Clinical and Vaccine Immunology

Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges

(2011) Morgane Bomsel et al.   IMMUNITY

Virosome-Formulated Plasmodium falciparum AMA-1 & CSP Derived Peptides as Malaria Vaccine: Randomized Phase 1b Trial in Semi-Immune Adults & Children

(2011) Patrick Georges Cech et al.   PLoS One

Generation of Merkel Cell Polyomavirus (MCV)-Like Particles and Their Application to Detection of MCV Antibodies

(2010) A. Touze et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Aerosolized PLA and PLGA Nanoparticles Enhance Humoral, Mucosal and Cytokine Responses to Hepatitis B Vaccine

(2010) Chandan Thomas et al.   MOLECULAR PHARMACEUTICS

Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation

(2010) Toon Stegmann et al.   VACCINE

Dendritic Cells in Innate and Adaptive Immune Responses against Influenza Virus

(2009) Artur Summerfield et al.   Viruses-Basel

Epaxal®: a virosomal vaccine to prevent hepatitis A infection

(2008) Patrick A Bovier   Expert Review of Vaccines

Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial

(2008) Fiona M. Thompson et al.   PLoS One

Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial

(2007) Michel Adamina et al.   Contemporary Clinical Trials